Altering the course of Ovarian cancer with emerging therapies in the horizon
May 4, 2020
Many players such as Immunogen, On Target Laboratories, ImmunoVaccine Technologies, OncoQuest, Precigen, and some others are involved in developing therapies to accelerate ...
Read More
Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses
Jun 16, 2020
Non-small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030. Worldwide, cancer claimed the lives of approximately 9.6 mil...
Read More
Malignant Pleural Mesothelioma Upcoming Therapies
Jul 2, 2020
Malignant pleural mesothelioma treatment market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and Yervoy, which have shown promising ant...
Read More
Omega’s sixth funding round; Correvio’s drug failure; and BIMA acquisition
Jun 29, 2020
A leading global international investment firm, Omega Funds has announced the closure of its sixth fundraising USD 438 Million. More than decade old Life Sciences-based inv...
Read More
Metastatic Pancreatic Cancer Market Size: Emerging therapies, Unmet needs and Forecast analysis
Feb 14, 2020
Pancreas is a gland which has two components exocrine component and endocrine component. The exocrine component which is responsible for making proteins/ enzymes and ...
Read More
Non-small cell lung cancer emerging therapies
Feb 5, 2020
The Non-small cell lung cancer therapeutics market is anticipated to improve owing to better diagnostics methodologies and treatment options across the world. This would ex...
Read More
Non-Small Cell Lung Cancer Market: Treatments and Market Forecast
Jul 2, 2020
An estimated number of 18.1 million new cancer cases were registered last year, according to A Cancer Journal for Clinicians 2018;0:1‐31. Moreover, it is a leading cause ...
Read More
Refractory Metastatic Melanoma Market
Feb 13, 2020
The cases of Melanoma have been on a hike for the past thirty years making it the fifth most common cancer among people. By the end of the year 2019, an estimated number of...
Read More
HR-positive/ HER2-negative Breast Cancer Market Insights: Upcoming Therapies and Market Analysis
Jun 29, 2020
Breast cancer is a serious and most common problem in developed as well as developing countries.About 1 in 8 U.S. women summing up to 12% are at the risk of developing inva...
Read More
Global Burden of Liver cancer: Is it rising?
Feb 5, 2020
Liver Cancer incidence is not as high as the incidence of breast or lung cancer. However, rising diagnosis rates reveal another story. According to a survey, Liver cancer h...
Read More
Flagship Pioneering launches Omega Therapeutics; EU nod to Vitrakvi; Bluebird Bio reveals positive results of Starbeam clinical trial
Feb 14, 2020
Flagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine. The launch of Omega therapeutics was planned to focus on epigenetic dr...
Read More
Boehringer Ingelheim ties up with Inflammasome Therapeutics
Jun 26, 2020
Boehringer Ingelheim and Inflammasome Therapeutics Inc. have announced that they have entered into a definitive a co-development and license agreement to develop therapies ...
Read More
Metastatic HER2-Positive Breast Cancer
Feb 5, 2020
Breast cancer is not a single disease leading to abnormal cell division in breast tissues. In the United States, it is estimated that more than 40,000 women will die from b...
Read More
How Spinal Muscular Atrophy Therapies transform market?
Jun 30, 2020
Spinal Muscular Atrophy is a rare and the second most fatal autosomal recessive genetic disorder with an incidence of 1 in 6000 to 1 in 10,000 births. Globally talking, SMA...
Read More
Imfinzi fails. What’s next in Non-small cell lung cancers Market Scenario?
Jul 2, 2020
The drug Imfinzi (durvalumab) has failed to come up as an effective treatment option for treating non-small cell lung cancer (NSCLC). The result of the NEPTUNE study was no...
Read More
